Literature DB >> 18281197

Quetiapine at high doses for the treatment of refractory schizophrenia.

Douglas L Boggs, Deanna L Kelly, Stephanie Feldman, Robert P McMahon, Matthew W Nelson, Yang Yu, Robert R Conley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18281197      PMCID： PMC2535767          DOI： 10.1016/j.schres.2008.01.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  7 in total

1.  High-dose quetiapine in treatment refractory schizophrenia.

Authors:  Joseph M Pierre; Donna A Wirshing; William C Wirshing; J Michael Rivard; Russell Marks; John Mendenhall; Karen Sheppard; David G Saunders
Journal:  Schizophr Res       Date:  2005-03-01       Impact factor: 4.939

2.  Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Authors:  Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Jeffrey A Lieberman; Leslie Citrome; Brian Sheitman; Miranda Chakos; Joseph P McEvoy
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

3.  Effect of antipsychotic withdrawal on extrapyramidal symptoms: statistical methods for analyzing single-sample repeated-measures data.

Authors:  S Arndt; C S Davis; D D Miller; N C Andreasen
Journal:  Neuropsychopharmacology       Date:  1993-01       Impact factor: 7.853

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

5.  Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.

Authors:  A F Breier; A K Malhotra; T P Su; D A Pinals; I Elman; C M Adler; R T Lafargue; A Clifton; D Pickar
Journal:  Am J Psychiatry       Date:  1999-02       Impact factor: 18.112

6.  Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia.

Authors:  Robert R Conley; Deanna L Kelly; Matthew W Nelson; Charles M Richardson; Stephanie Feldman; Rhonda Benham; Patricia Steiner; Yang Yu; Ijaz Khan; Ron McMullen; Elizabeth Gale; Marie Mackowick; Raymond C Love
Journal:  Clin Neuropharmacol       Date:  2005 Jul-Aug       Impact factor: 1.592

7.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Authors:  John M Kane; Stefan Leucht; Daniel Carpenter; John P Docherty
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384
  7 in total
  2 in total

1.  Case reports of patients with treatment-resistant schizophrenia and related psychotic disorders intolerant to clozapine responding to high doses of quetiapine.

Authors:  Poornima Chandrappa; Luk Ho
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

2.  Antipsychotic effects of quetiapine in naturalistic long term follow up study.

Authors:  Jung-Sun Lee; Joon Ho Ahn; Do-Hoon Kim; Jong-Jin Kim; Tae-Young Kim; So-Young Yoo; Dong-Geun Lee; Sang-Hyuk Lee; Se-Won Lim; Weon-Jeong Lim; Il-Kyung Jung; Hae-Kyung Jung; Dong-Hwan Cho; In-Hee Cho; Chang-Yoon Kim
Journal:  Psychiatry Investig       Date:  2010-05-04       Impact factor: 2.505
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.